Related Experiment Video
Updated: Feb 19, 2026

Dermoscopy Aids in the Diagnosis of Discoid Lupus Erythematosus
Published on: May 16, 2025
Dasatinib-induced Seborrheic Dermatitis-like Eruption
Ryan R Riahi1, Philip R Cohen1
1Dr. Riahi is with DermSurgery Associates, Houston, Texas.
Abstract:
Dasatinib is an oral tyrosine kinase inhibitor approved for imatinib-resistant chronic myelogenous leukemia. It has been investigated in treating other neoplasms, including non-small-cell lung cancer and a subset of melanomas. Seborrheic dermatitis is characterized by erythematous patches or plaques with scaling typically affecting the external ear, glabella, hair-bearing areas of the face, nasolabial fold, and scalp. Antitumor agents are often associated with mucocutaneous side effects, including seborrheic dermatitis. We describe the case of a 79-year-old woman with a history of sinonasal melanoma who developed a seborrheic dermatitis-like eruption while taking dasatinib. We also review the molecular abnormalities associated with melanoma, summarize the mucocutaneous side effects of dasatinib, and list the other antineoplastic agents associated with a seborrheic dermatitis-like eruption.
Insights
Dasatinib, used for chronic myelogenous leukemia, can cause seborrheic dermatitis-like skin issues. This case highlights a patient with melanoma experiencing this side effect during dasatinib treatment.
Area of Science:
- Oncology
- Dermatology
Background:
- Dasatinib is a tyrosine kinase inhibitor approved for imatinib-resistant chronic myelogenous leukemia.
- It is also explored for treating other cancers like non-small-cell lung cancer and melanoma.
- Mucocutaneous side effects, such as seborrheic dermatitis, are common with antitumor agents.
Observation:
- A 79-year-old woman with a history of sinonasal melanoma developed a seborrheic dermatitis-like eruption.
- The patient was undergoing treatment with dasatinib.
Findings:
- The case report details a patient experiencing a seborrheic dermatitis-like eruption while on dasatinib therapy.
- The study reviews molecular abnormalities in melanoma and the mucocutaneous side effects of dasatinib.
- Other antineoplastic agents linked to seborrheic dermatitis-like eruptions are also identified.
Implications:
- This case underscores the potential for dasatinib to induce seborrheic dermatitis-like reactions.
- Understanding these side effects is crucial for managing patients undergoing tyrosine kinase inhibitor therapy.
- Further research may elucidate the mechanisms behind these drug-induced dermatologic conditions.
More Related Videos
09:32Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
Published on: October 17, 2025
09:15Author Spotlight: Optimized Protocol for Detecting Antigen-Specific T Cells in Mouse Lungs Using Tetramers
Published on: July 19, 2024
Related Concept Videos
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Drug Toxicity: Allergic Reactions
Accessory Structures of the Skin: Sebaceous Glands
These glands that produce the oils on the skin and hair are holocrine glands. The mature...
Skin Diseases and Disorders
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
Transdermal Drug Delivery Systems
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists